KEGG   DRUG: Crovalimab
Entry
D11696                      Drug                                   
Name
Crovalimab (USAN/INN);
Crovalimab (genetical recombination) (JAN);
Crovalimab-akkz;
Piasky (TN)
Product
Formula
C6430H9974N1726O2026S46
Exact mass
145257.7649
Mol weight
145347.42
Sequence
(Heavy chain)
QVQLVESGGG LVQPGRSLRL SCAASGFTVH SSYYMAWVRQ APGKGLEWVG AIFTGSGAEY
KAEWAKGRVT ISKDTSKNQV VLTMTNMDPV DTATYYCASD AGYDYPTHAM HYWGQGTLVT
VSSASTKPGS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
QSSGLYSLSS VVTVPSSSLG TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL
RRGPKVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK
SRWQQGNVFS CSVLHEALHA HYTRKELSLS P
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SSLAWYQQKP GKAPKLLIYG ASETESGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQN TKVGSSYGNT FGGGTKVEIK RTVAAPSVFI
FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS
TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC
(Disulfide bridge: H22-H97, H150-H206, H226-L217, H232-H'232, H235-H'235, H267-H327, H373-H431, H'22-H'97, H'150-H'206, H'226-L'217, H'267-H'327, H'373-H'431, L23-L88, L137-L197, L'23-L'88, L'137-L'197)
  Type
Peptide
Remark
Therapeutic category: 6399
ATC code: L04AJ07
Product: D11696<JP/US>
Efficacy
Anti-complement C5 antibody
  Disease
Paroxysmal nocturnal hemoglobinuria [DS:H01053]
  Type
Monoclonal antibody
Comment
Treatment of paroxysmal nocturnal hemoglobinuria (PNH)
Target
C5 [HSA:727] [KO:K03994]
  Pathway
hsa04080  Neuroactive ligand-receptor interaction
hsa04610  Complement and coagulation cascades
  Network
nt06513  Complement cascade
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AJ Complement inhibitors
     L04AJ07 Crovalimab
      D11696  Crovalimab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Complement Inhibitors
    Crovalimab
     D11696  Crovalimab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D11696  Crovalimab (USAN/INN); Crovalimab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Peptidases and inhibitors
  Peptidase inhibitors
   alpha2M family
    C5
     D11696  Crovalimab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11696
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11696
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11696
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11696
Other DBs
CAS: 1917321-26-6
PubChem: 405226562
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system